Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series
详细信息 查看全文
- 作者：Attaphol Pawarode1 ; pawarode@med.umich.edu" class="auth_mail" title="E-mail the corresponding author ; Shin Mineishi2 ; Pavan Reddy1 ; Thomas M. Braun3 ; Yasser A. Khaled4 ; Sung W. Choi1 ; John M. Magenau1 ; Andrew C. Harris1 ; James A. Connelly1 ; Carrie L. Kitko1 ; Brian L. Parkin1 ; Steven C. Goldstein1 ; Gregory A. Yanik1 ; John E. Levine1 ; James L. Ferrara5 ; Daniel R. Couriel1
- 关键词：Multiple myeloma ; Allogeneic ; Myeloablative ; Reduced toxicity ; Prospective ; Fludarabine ; Busulfan
- 刊名：Biology of Blood and Marrow Transplantation
- 出版年：2016
- 出版时间：January 2016
- 年：2016
- 卷：22
- 期：1
- 页码：54-60
- 全文大小：522 K
文摘
- •
We prospectively studied a myeloablative conditioning regimen with reduced toxicity, (fludarabine and busulfan × 4), followed by allogeneic hematopoietic cell transplantation for high-risk multiple myeloma.
- •
The regimen was safe, without early toxic death or graft failure. Treatment-related mortality was decreased, when compared with other conventional myeloablative regimens.
- •
The overall outcomes were not improved because of ongoing high relapse and chronic graft-versus-host disease rates.
- •
Additional strategies (eg, combining a targeted agent with graft-versus-host disease–modulating property, especially a proteasome inhibitor, or maintenance therapy) are needed.